Volume Alert - MYL 56.10 Mylan Inc $MYL Hit a high today of 56.69 Closing the day 10:30 at 56.10 +0.97 +1.76% With a day low of 55.05 and a total volume of 1,105,594.
MYL Recent Posts: http://investorshangout.com/Mylan-Inc-MYL-54841/
MYL Mylan Inc Recent Headline News
Teva wins Actonel patent appeal
Seeking Alpha - at Seeking Alpha - 1 hr 41 mins ago
ACT: 268.20 (+20.26), MYL: 56.08 (+0.95), TEVA: 57.34 (+0.10)
Why Mylan Will Continue To Soar
Main Street Wins - at Seeking Alpha - Tue Nov 18, 8:50AM CST
MYL: 56.08 (+0.95), TEVA: 57.34 (+0.10)
Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:30PM CST
Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2014 results on Nov 19.
IPXL: 29.49 (+0.78), MNK: 89.33 (+0.90), BIIB: 305.34 (+2.92), MYL: 56.08 (+0.95)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Mylan Is Up 3.2% (MYL)
Comtex SmarTrend(R) - Mon Nov 17, 2:31PM CST
When Mylan (NASDAQ:MYL) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $1.14 on sales of $2.1 billion. Mylan actually reported earnings of $1.16 per share on sales of $2.1 billion, beating EPS estimates by $0.02 and beating revenue estimates by $32.3 million. Since the company's report, shares of Mylan have risen from $52.37 to $54.05, representing a gain of 3.2% in the past 18 days.
MYL: 56.08 (+0.95)
AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 29.49 (+0.78), AXGN: 2.70 (+0.06), AKRX: 38.35 (+0.46), MYL: 56.08 (+0.95)
InsiderInsights.com Daily Round Up 11/12/14: DVA, PSEC, MRC, SUMR
InsiderInsights - at Seeking Alpha - Fri Nov 14, 3:44PM CST
HAS: 56.04 (-0.33), CJES: 18.41 (-0.10), FB: 74.45 (+0.21), MRC: 21.75 (+0.05), SUMR: 2.89 (+0.10), MYL: 56.08 (+0.95), GOOG: 535.27 (-1.24), GSAT: 2.59 (-0.21), CHRS: 13.26 (+0.11), GGP: 25.98 (+0.13), DVA: 75.44 (-0.07), Q: 57.33 (+0.90), SPW: 93.42 (+0.94), RCPT: 102.87 (-1.35), DATA: 82.80 (-0.51), X: 35.84 (-0.27), PSEC: 9.65 (-0.01), SCHW: 28.78 (+0.23), ERII: 4.88 (+0.18)
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 89.33 (+0.90), KBIO: 1.99 (unch), AKRX: 38.35 (+0.46), MYL: 56.08 (+0.95)
Watch for Mylan to Potentially Pullback After Gaining 1.73% Yesterday
Comtex SmarTrend(R) - Thu Nov 13, 4:15PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.16 to a high of $56.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $54.23 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.08 (+0.95)
Mylan Set to Possibly Pullback After Yesterday's Rally of 1.73%
Comtex SmarTrend(R) - Thu Nov 13, 4:15PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.16 to a high of $56.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $54.23 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.08 (+0.95)
Trade-Ideas: Mylan (MYL) Is Today's "Barbarian At The Gate" Stock
at The Street - Thu Nov 13, 10:10AM CST
Trade-Ideas LLC identified Mylan (MYL) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
MYL: 56.08 (+0.95)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 89.60 (+0.59), VRX: 142.95 (+6.22), ALXN: 192.45 (+5.67), AMGN: 161.48 (+2.34), MYL: 56.08 (+0.95), ILMN: 191.35 (+8.44), CELG: 106.82 (+2.46)
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 89.33 (+0.90), IPXL: 29.49 (+0.78), KBIO: 1.99 (unch), MYL: 56.08 (+0.95)
Comparing America's 3 Largest Generic Drugs Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 07, 9:05AM CST
ZTS: 43.92 (-0.31), ACT: 268.20 (+20.26), MYL: 56.08 (+0.95)
Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors
PR Newswire - Fri Nov 07, 7:00AM CST
Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
MYL: 56.08 (+0.95)
Mylan reports market availability of generic Loestrin 24 Fe for contraception
M2 - Thu Nov 06, 7:27AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the introduction of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate in the US with immediate effect.
MYL: 56.08 (+0.95)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 89.33 (+0.90), ACT: 268.23 (+20.29), MYL: 56.08 (+0.95), TEVA: 57.34 (+0.10)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.50 (+0.12), BCR: 166.85 (+2.04), INCY: 69.36 (-0.34), MYL: 56.08 (+0.95), AEGR: 20.66 (+0.74)
Mylan Launches Generic Loestrin 24 Fe®
PR Newswire - Wed Nov 05, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan has begun shipping product.
MYL: 56.08 (+0.95)
Mylan Is Near All-Time High Levels But Still A Strong Buy
Kanak Kanti De - at Seeking Alpha - Mon Nov 03, 12:10PM CST
MYL: 56.08 (+0.95)
Watch for Shares of Mylan (MYL) to Approach Resistance at $53.74
Comtex SmarTrend(R) - Fri Oct 31, 12:59PM CDT
Shares of Mylan (NASDAQ:MYL) have bullishly opened above the pivot of $51.77 today and have reached the first resistance level of $53.06. Analysts will be watching for a cross of the next upside pivot targets of $53.74 and $55.71.
MYL: 56.08 (+0.95)
MYL Recent Posts: http://investorshangout.com/Mylan-Inc-MYL-54841/
MYL Mylan Inc Recent Headline News
Teva wins Actonel patent appeal
Seeking Alpha - at Seeking Alpha - 1 hr 41 mins ago
ACT: 268.20 (+20.26), MYL: 56.08 (+0.95), TEVA: 57.34 (+0.10)
Why Mylan Will Continue To Soar
Main Street Wins - at Seeking Alpha - Tue Nov 18, 8:50AM CST
MYL: 56.08 (+0.95), TEVA: 57.34 (+0.10)
Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:30PM CST
Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2014 results on Nov 19.
IPXL: 29.49 (+0.78), MNK: 89.33 (+0.90), BIIB: 305.34 (+2.92), MYL: 56.08 (+0.95)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Mylan Is Up 3.2% (MYL)
Comtex SmarTrend(R) - Mon Nov 17, 2:31PM CST
When Mylan (NASDAQ:MYL) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $1.14 on sales of $2.1 billion. Mylan actually reported earnings of $1.16 per share on sales of $2.1 billion, beating EPS estimates by $0.02 and beating revenue estimates by $32.3 million. Since the company's report, shares of Mylan have risen from $52.37 to $54.05, representing a gain of 3.2% in the past 18 days.
MYL: 56.08 (+0.95)
AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 29.49 (+0.78), AXGN: 2.70 (+0.06), AKRX: 38.35 (+0.46), MYL: 56.08 (+0.95)
InsiderInsights.com Daily Round Up 11/12/14: DVA, PSEC, MRC, SUMR
InsiderInsights - at Seeking Alpha - Fri Nov 14, 3:44PM CST
HAS: 56.04 (-0.33), CJES: 18.41 (-0.10), FB: 74.45 (+0.21), MRC: 21.75 (+0.05), SUMR: 2.89 (+0.10), MYL: 56.08 (+0.95), GOOG: 535.27 (-1.24), GSAT: 2.59 (-0.21), CHRS: 13.26 (+0.11), GGP: 25.98 (+0.13), DVA: 75.44 (-0.07), Q: 57.33 (+0.90), SPW: 93.42 (+0.94), RCPT: 102.87 (-1.35), DATA: 82.80 (-0.51), X: 35.84 (-0.27), PSEC: 9.65 (-0.01), SCHW: 28.78 (+0.23), ERII: 4.88 (+0.18)
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 89.33 (+0.90), KBIO: 1.99 (unch), AKRX: 38.35 (+0.46), MYL: 56.08 (+0.95)
Watch for Mylan to Potentially Pullback After Gaining 1.73% Yesterday
Comtex SmarTrend(R) - Thu Nov 13, 4:15PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.16 to a high of $56.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $54.23 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.08 (+0.95)
Mylan Set to Possibly Pullback After Yesterday's Rally of 1.73%
Comtex SmarTrend(R) - Thu Nov 13, 4:15PM CST
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $53.16 to a high of $56.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $54.23 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 56.08 (+0.95)
Trade-Ideas: Mylan (MYL) Is Today's "Barbarian At The Gate" Stock
at The Street - Thu Nov 13, 10:10AM CST
Trade-Ideas LLC identified Mylan (MYL) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
MYL: 56.08 (+0.95)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 89.60 (+0.59), VRX: 142.95 (+6.22), ALXN: 192.45 (+5.67), AMGN: 161.48 (+2.34), MYL: 56.08 (+0.95), ILMN: 191.35 (+8.44), CELG: 106.82 (+2.46)
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 89.33 (+0.90), IPXL: 29.49 (+0.78), KBIO: 1.99 (unch), MYL: 56.08 (+0.95)
Comparing America's 3 Largest Generic Drugs Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 07, 9:05AM CST
ZTS: 43.92 (-0.31), ACT: 268.20 (+20.26), MYL: 56.08 (+0.95)
Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors
PR Newswire - Fri Nov 07, 7:00AM CST
Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
MYL: 56.08 (+0.95)
Mylan reports market availability of generic Loestrin 24 Fe for contraception
M2 - Thu Nov 06, 7:27AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the introduction of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate in the US with immediate effect.
MYL: 56.08 (+0.95)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 89.33 (+0.90), ACT: 268.23 (+20.29), MYL: 56.08 (+0.95), TEVA: 57.34 (+0.10)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.50 (+0.12), BCR: 166.85 (+2.04), INCY: 69.36 (-0.34), MYL: 56.08 (+0.95), AEGR: 20.66 (+0.74)
Mylan Launches Generic Loestrin 24 Fe®
PR Newswire - Wed Nov 05, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan has begun shipping product.
MYL: 56.08 (+0.95)
Mylan Is Near All-Time High Levels But Still A Strong Buy
Kanak Kanti De - at Seeking Alpha - Mon Nov 03, 12:10PM CST
MYL: 56.08 (+0.95)
Watch for Shares of Mylan (MYL) to Approach Resistance at $53.74
Comtex SmarTrend(R) - Fri Oct 31, 12:59PM CDT
Shares of Mylan (NASDAQ:MYL) have bullishly opened above the pivot of $51.77 today and have reached the first resistance level of $53.06. Analysts will be watching for a cross of the next upside pivot targets of $53.74 and $55.71.
MYL: 56.08 (+0.95)
